Harrow (HROW) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $28.75, +5.54% vs the prior close of $27.24.
- Volume 582.90K shares, 1.0x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
HROW jumps 5.5% to $28.75. Closed at $28.75, +5.54% vs the prior close of $27.24. Day range $27.03–$28.92, opened at $27.14.
HROW daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — HROW jumps 5.5% to $28.75
- Closed at $28.75, +5.54% vs the prior close of $27.24. Day range $27.03–$28.92, opened at $27.14.
- Volume was 582.90K shares, 1.0x its 50-day average of 593.38K.
- Price is -18.8% vs its 50-day average ($35.42) and -27.3% vs its 200-day average ($39.53).
- 52-week range $26.96–$54.85; today's close sits at 6% of that range, 47.6% below the 52-week high.
Oct 14, 2026 — HROW slides 3.5% to $27.24, a 52-week low, 5 down days in a row
- Closed at $27.24, -3.54% vs the prior close of $28.24. Day range $26.96–$28.31, opened at $28.00.
- Volume was 660.30K shares, 1.1x its 50-day average of 587.54K.
- Price is -23.6% vs its 50-day average ($35.63) and -31.3% vs its 200-day average ($39.64).
- 52-week range $26.96–$54.85; today's close sits at 1% of that range, 50.3% below the 52-week high.
- That makes 5 straight losses.
Oct 13, 2026 — HROW dips 3.0% to $28.24, a 52-week low, 4 down days in a row
- Closed at $28.24, -2.99% vs the prior close of $29.11. Day range $28.03–$29.43, opened at $28.96.
- Volume was 800.90K shares, 1.4x its 50-day average of 579.53K.
- Price is -21.3% vs its 50-day average ($35.88) and -29.0% vs its 200-day average ($39.75).
- 52-week range $27.00–$54.85; today's close sits at 4% of that range, 48.5% below the 52-week high.
- That makes 4 straight losses.
Oct 12, 2026 — HROW dips 0.9% to $29.11, a 3-month low, 3 down days in a row
- Closed at $29.11, -0.85% vs the prior close of $29.36. Day range $28.86–$29.73, opened at $29.38.
- Volume was 577.00K shares, 1.0x its 50-day average of 573.22K.
- Price is -19.4% vs its 50-day average ($36.10) and -27.0% vs its 200-day average ($39.86).
- 52-week range $27.00–$54.85; today's close sits at 8% of that range, 46.9% below the 52-week high.
- That makes 3 straight losses.
Oct 9, 2026 — HROW slides 3.8% to $29.36, a 3-month low on 2.4x normal volume
- Closed at $29.36, -3.80% vs the prior close of $30.52. Day range $27.00–$30.90, opened at $30.73.
- Volume was 1.35M shares, 2.4x its 50-day average of 552.00K — unusually heavy trading.
- Price is -19.1% vs its 50-day average ($36.29) and -26.5% vs its 200-day average ($39.96).
- 52-week range $27.00–$54.85; today's close sits at 8% of that range, 46.5% below the 52-week high.
Oct 8, 2026 — HROW dips 0.3% to $30.52
- Closed at $30.52, -0.33% vs the prior close of $30.62. Day range $30.00–$31.11, opened at $30.35.
- Volume was 566.00K shares, 1.0x its 50-day average of 547.93K.
- Price is -16.4% vs its 50-day average ($36.49) and -23.8% vs its 200-day average ($40.06).
- 52-week range $28.54–$54.85; today's close sits at 8% of that range, 44.4% below the 52-week high.
Oct 7, 2026 — HROW rises 0.9% to $30.62
- Closed at $30.62, +0.89% vs the prior close of $30.35. Day range $29.90–$31.11, opened at $30.09.
- Volume was 708.20K shares, 1.3x its 50-day average of 545.16K.
- Price is -16.5% vs its 50-day average ($36.65) and -23.7% vs its 200-day average ($40.14).
- 52-week range $28.54–$54.85; today's close sits at 8% of that range, 44.2% below the 52-week high.
Oct 6, 2026 — HROW dips 0.8% to $30.35, a 3-month low
- Closed at $30.35, -0.75% vs the prior close of $30.58. Day range $29.85–$30.90, opened at $30.86.
- Volume was 421.70K shares, 0.8x its 50-day average of 547.06K.
- Price is -17.6% vs its 50-day average ($36.82) and -24.5% vs its 200-day average ($40.21).
- 52-week range $28.54–$54.85; today's close sits at 7% of that range, 44.7% below the 52-week high.
Oct 5, 2026 — HROW rises 0.3% to $30.58
- Closed at $30.58, +0.33% vs the prior close of $30.48. Day range $30.43–$31.43, opened at $31.43.
- Volume was 587.00K shares, 1.1x its 50-day average of 553.09K.
- Price is -17.3% vs its 50-day average ($36.97) and -24.1% vs its 200-day average ($40.28).
- 52-week range $28.54–$54.85; today's close sits at 8% of that range, 44.2% below the 52-week high.
- SEC filings that day: 8-K.
Oct 2, 2026 — HROW dips 0.4% to $30.48, a 3-month low, 8 down days in a row
- Closed at $30.48, -0.42% vs the prior close of $30.61. Day range $30.15–$30.97, opened at $30.83.
- Volume was 566.10K shares, 1.0x its 50-day average of 549.09K.
- Price is -17.9% vs its 50-day average ($37.12) and -24.5% vs its 200-day average ($40.35).
- 52-week range $28.54–$54.85; today's close sits at 7% of that range, 44.4% below the 52-week high.
- That makes 8 straight losses.
HROW latest news & SEC filings
Every SEC filing by or about HROW in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 5, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 2.01 — Completed an acquisition or sale of assets.
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 4, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Aug 21, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 17, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Shojaei Amir sold 11,250 shares at $40.00 (≈$450.00K) on Aug 14, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 10, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $70.66M (prior year $63.74M) (+10.9% vs Jun 30, 2025)
- Net income: -$17.27M (prior year $5.00M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.46 (prior year $0.13) (loss widened vs Jun 30, 2025)
Aug 10, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Jul 31, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jun 22, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 22, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 22, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 22, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.07 — Reported shareholder vote results.
Things to know before you trade HROW
- Last results release: Aug 10, 2026 (8-K Item 2.02). Previous ones: May 11, 2026, Mar 2, 2026, Feb 2, 2026. Based on that rhythm, the next report is likely around Nov 9, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.77% (largest 5.5%).
- Liquidity: about 654.13K shares (≈$18.81M) trade per day on average.
- 52-week position: $28.75 vs a range of $26.96–$54.85 (6% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 4 open-market buys, 7 sales; latest: Amir Shojaei sold 11,250 shares on Aug 14, 2026.
- Latest filings: 8-K Oct 5, 2026; 8-K Sep 4, 2026; 10-Q Aug 10, 2026.
- Share count: 37.49M shares outstanding (Aug 6, 2026), +1.3% vs a year earlier.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
HROW market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 27.14 | 28.92 | 27.03 | 28.75 | 582.90K |
| Oct 14, 2026 | 28.00 | 28.31 | 26.96 | 27.24 | 660.30K |
| Oct 13, 2026 | 28.96 | 29.43 | 28.03 | 28.24 | 800.90K |
| Oct 12, 2026 | 29.38 | 29.73 | 28.86 | 29.11 | 577.00K |
| Oct 9, 2026 | 30.73 | 30.90 | 27.00 | 29.36 | 1.35M |
| Oct 8, 2026 | 30.35 | 31.11 | 30.00 | 30.52 | 566.00K |
| Oct 7, 2026 | 30.09 | 31.11 | 29.90 | 30.62 | 708.20K |
| Oct 6, 2026 | 30.86 | 30.90 | 29.85 | 30.35 | 421.70K |
| Oct 5, 2026 | 31.43 | 31.43 | 30.43 | 30.58 | 587.00K |
| Oct 2, 2026 | 30.83 | 30.97 | 30.15 | 30.48 | 566.10K |
| Oct 1, 2026 | 30.55 | 31.10 | 30.28 | 30.61 | 596.90K |
| Sep 30, 2026 | 31.62 | 31.86 | 30.76 | 30.80 | 514.40K |
| Sep 29, 2026 | 31.60 | 31.82 | 31.09 | 31.40 | 396.50K |
| Sep 28, 2026 | 32.61 | 32.88 | 30.19 | 31.60 | 851.80K |
| Sep 25, 2026 | 33.00 | 33.28 | 32.58 | 33.07 | 373.00K |
| Sep 24, 2026 | 33.49 | 33.50 | 32.50 | 33.10 | 397.80K |
| Sep 23, 2026 | 34.23 | 34.50 | 33.41 | 33.60 | 348.00K |
| Sep 22, 2026 | 34.00 | 34.87 | 33.68 | 34.45 | 428.20K |
| Sep 21, 2026 | 33.21 | 34.31 | 32.64 | 33.92 | 611.40K |
| Sep 18, 2026 | 32.93 | 33.34 | 31.90 | 33.08 | 1.74M |
About Harrow
Harrow (HROW) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in NASHVILLE, TN. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1360214.
HROW board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Mark L Baum | CHIEF EXECUTIVE OFFICER | May 15, 2026 |
| Adrienne L Graves | Director | Jun 22, 2026 |
| Lauren P Silvernail | Director | Jun 22, 2026 |
| Perry J. Sternberg | Director | Jun 22, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Mark L Baum | CHIEF EXECUTIVE OFFICER | May 15, 2026 |
| Andrew R. Boll | PRESIDENT AND CFO | May 15, 2026 |
| Francis William Jr Mullery | CEO, ImprimisRx | Oct 10, 2025 |
| Amir Shojaei | CHIEF SCIENTIFIC OFFICER | Aug 17, 2026 |
| Patrick William Sullivan | CHIEF COMMERCIAL OFFICER | Feb 2, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 14, 2026 | Amir Shojaei | Sale | 11,250 | $40.00 |
| May 18, 2026 | Lauren P Silvernail | Buy | 1,000 | $31.00 |
| May 18, 2026 | Adrienne L Graves | Buy | 1,000 | $31.07 |
| May 14, 2026 | Mark L Baum | Buy | 10,000 | $30.20 |
| May 14, 2026 | Andrew R. Boll | Buy | 3,500 | $29.90 |
| Mar 4, 2026 | Management Inc. Opaleye | Sale | 134,000 | $39.67 |
| Mar 4, 2026 | Management Inc. Opaleye | Sale | 4,263 | $39.67 |
| Mar 3, 2026 | Management Inc. Opaleye | Sale | 1,309 | $39.15 |
| Mar 3, 2026 | Management Inc. Opaleye | Sale | 59,000 | $39.15 |
| Feb 27, 2026 | Management Inc. Opaleye | Sale | 5,000 | $54.18 |
| Jan 6, 2026 | Management Inc. Opaleye | Sale | 20,000 | $53.35 |
HROW financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $272.30M | $-5.14M | -0.14 | $43.86M |
| Dec 31, 2024 | $199.61M | $-17.48M | -0.49 | $-22.20M |
| Dec 31, 2023 | $130.19M | $-24.41M | -0.75 | $3.84M |
| Dec 31, 2022 | $88.59M | $-14.09M | -0.51 | $1.71M |
| Dec 31, 2021 | $72.48M | $-18.01M | — | $5.08M |
Latest balance sheet: total assets $416.82M, total liabilities $401.97M, cash $83.89M (as of Jun 30, 2026).
HROW earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 10, 2026 | 8-K Item 2.02 (results) | $40.70 |
| May 11, 2026 | 8-K Item 2.02 (results) | $38.04 |
| Mar 2, 2026 | 8-K Item 2.02 (results) | $53.59 |
| Feb 2, 2026 | 8-K Item 2.02 (results) | $44.90 |
| Nov 10, 2025 | 8-K Item 2.02 (results) | $34.14 |
| Aug 11, 2025 | 8-K Item 2.02 (results) | $33.74 |
| May 8, 2025 | 8-K Item 2.02 (results) | $23.59 |
| Mar 27, 2025 | 8-K Item 2.02 (results) | $27.87 |
| Mar 17, 2025 | 8-K Item 2.02 (results) | $23.32 |
| Nov 14, 2024 | 8-K Item 2.02 (results) | $42.86 |
| Aug 7, 2024 | 8-K Item 2.02 (results) | — |
| May 13, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on HROW
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.